Last reviewed · How we verify

NCT06053333

Social Determinants of Health in Hepatobiliary Cancer Patients

Recruiting now Last updated 4 February 2026
What this trial tests

trial testing Non-Interventional Study in Malignant Hepatobiliary Neoplasm in 400 participants. Currently enrolling.

Timeline
17 July 2023
Primary endpoint
17 July 2028
17 July 2028

Quick facts

Lead sponsorMayo Clinic
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment400
Start date17 July 2023
Primary completion17 July 2028
Estimated completion17 July 2028
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Malignant Hepatobiliary Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates barriers to receiving care and risks associated with developing cancer among patients diagnosed with hepatobiliary cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Non-Interventional Study

Trials testing the same drug.

Other recruiting trials for Malignant Hepatobiliary Neoplasm

Currently open trials in the same condition.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06053333.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing